Northstrive Biosciences Inc., a subsidiary of PMGC Holdings Inc., announced on March 10, 2025, that it has scheduled a pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) for April 23, 2025.
This meeting is a crucial step for EL-22, an obesity therapy leveraging a myostatin-engineered probiotic approach. The therapy aims to address the pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists.
The pre-IND meeting will allow Northstrive to discuss its nonclinical studies and clinical development plans for EL-22 with the FDA. This engagement is essential for advancing EL-22 towards an IND application and subsequent clinical trials.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.